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Abstract We investigated whether alterations of the
Her2 gene could be detected in breast cancer samples
following primary chemotherapy in advanced breast
cancer. The prospective study involved 23 patients with
stage-II, -III or -IV breast cancer. All patients were
treated with two to six cycles of fluorouracil-epirubicin
and/or cyclophosphamid/epi-docetaxel. The Her2 protein
and gene were assessed both on core needle biopsies prior
to and on surgical specimens after completing chemo-
therapy using immunohistochemistry (IHC) and fluores-
cence in situ hybridization (FISH) methods. Estrogen and
progesterone receptors (ER/PR) were also determined on
both samples using IHC. Her2 status was modified in
eight patients using IHC (35%) and in three patients using
FISH (13%). Changes in ER/PR expression were detected
in seven patients (30%). Our data suggest that alterations
of the Her2 gene can occur, although not usually after
primary or neoadjuvant chemotherapy. However, changes
in ER/PR status seem to be a more common event; thus,
both can lead to different therapeutic options. Intratu-
moral heterogeneity as well as sampling variations can
contribute to modification of the Her2 status after primary
chemotherapy.
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Introduction
Overexpression and/or amplification of the Her2 gene and
its protein product occur in approximately 25% of breast
cancers [1, 12, 13, 20]. Clinical importance of Her2
positivity in breast cancer has been investigated in nu-
merous previous studies, confirming shortened survival
and worse clinical outcome in Her2-positive patients [6,
23, 25, 27]. Preferential and comparative detection
methods of Her2 testing have been the subject of several
investigations as well [2, 15, 17, 26]. Nevertheless, sta-
bility of the Her2 gene and protein after chemotherapy
has not been thoroughly studied [7, 10, 22]. In routine
practice, it is not common to determine Her2 status on
breast cancer more than once during the disease course,
postulating gene stability.
We addressed the question whether alterations of the
Her2 gene and protein could be detected after primary
chemotherapy using immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH) methods on
samples prior to and after chemotherapy.
Materials and methods
Sample collection
Initially, 26 patients with advanced breast cancer were enrolled in
this prospective study, embracing a period from 2001 to 2004.
Clinical charts were accessible through the files of the Clinic of
Oncology of the University Hospital Zurich, Switzerland. Paraffin
blocks were available from each patient in the Institute of Clinical
Pathology of the University Hospital Zurich, Switzerland. Prior to
primary chemotherapy, core needle biopsies and fine needle aspi-
ration (FNA) were performed on all patients. In two patients (no. 6,
no.12), no tumor tissue could be obtained on core biopsies; in one
additional patient (no.19), there was no residual tumor confirmed
on histology after chemotherapy. Therefore, these patients were
excluded from the study later on. Mastectomy with axillary lym-
phonodectomy was the choice of surgery after completing che-
motherapy in all patients.
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Clinical features and histology
Of the patients, 22 presented with clinical stage-III or -IV breast
cancer or with an inflammatory carcinoma. In 4 patients, clinical
stage-II tumors were diagnosed. Positive axillary lymph nodes were
detected clinically in 21 of 26 patients. Patients’ ages ranged from
31 years to 72 years (mean age 50.3 years). All patients were
administered neoadjuvant or primary chemotherapy consisting of
several cycles (two to six) of fluorouracil-epirubicin and/or cy-
clophosphamid/epi-docetaxel.
All patients underwent core biopsy and FNA. In 2 patients, only
FNA could be performed (these 2 patients were expelled from the
cohort). The number of core biopsies per patient varied between
two and four. All core biopsies were embedded in paraffin after
fixation in 4% buffered formaldehyde. Slides 2-m thick were
prepared from each paraffin block and stained routinely with he-
matoxylin and eosin (H&E). The core biopsies confirmed invasive
carcinoma in 24 patients, 17 corresponding to invasive ductal and 7
to invasive lobular subtypes (Fig. 1A, C). Of the tumors, one was
well differentiated (G1), twelve were cases moderately differenti-
ated (G2) and 10 carcinomas were graded as poorly differentiated
(G3) on core biopsies according to the modified criteria of Bloom
and Richardson.
Mastectomy specimens were processed similarly to the core
biopsies. Paraffin blocks containing the best-preserved tumor area
on H&E were selected for determining prognostic parameters. All
immunohistochemical reactions and FISH analyses were performed
on 2-m thick slides. The mastectomy specimens revealed invasive
carcinoma in 22 patients, representing all tumor stages as follows:
pT1 (n=5), pT2 (n=9), pT3 (n=4) and pT4 (n=4). In one patient (no.
24), only lymphatic vessel invasion was detected without evidence
of residual tumor mass. Another patient displayed extensive fibrosis
without remaining invasive tumor cells or lymphatic invasion; for
this reason, this patient was excluded from the study as well.
Positive nodal status was confirmed in 13 of 23 cases. On histology,
4 cases diagnosed as lobular and ductal carcinoma, respectively, on
core biopsy were identified as mixed carcinoma with ductal and
lobular features—one case reported as ductal on the core biopsy
showed predominantly lobular differentiation on the mastectomy
specimen. Generally, there was abundant fibrosis in most mastec-
tomy specimens (Fig. 1B). The invasive tumor cells exhibited
typical histological changes after chemotherapy as hyperchromatic
nuclei, pleomorphism and nuclear or cytoplasmic inclusions
(Fig. 1D).
Immunohistochemistry
Her2
CB11 (anti-Her2 monoclonal antibody, Ventana, Tucson/AZ) was
carried out with the Benchmark automated staining system (Ven-
tana Medical Systems, Tucson/AZ). Cell membrane staining in-
tensity was evaluated as follows: no or any detectable membrane
signal in less then 10% of the tumor cells was considered as neg-
ative; weak incomplete membrane stain in more than 10% of the
tumor cells was scored as 1+; moderate to strong complete mem-
brane positivity in more than 10% of the tumor cells was considered
as 2+ and 3+, respectively (Fig. 1E, F).
Estrogen and progesterone receptors
The detection of estrogen receptor (ER) (clone 6F11, Ventana,
Tuscon/AZ) and progesterone receptor (PR) (clone 1A6, Ventana,
Tucson/AZ) was carried out with the Benchmark automated
staining system according to the manufacturers’ prescriptions. For
scoring of the reactions for ER and PR, the number of positively
stained nuclei was assessed as follows: + 10%, ++ 50%, +++
80%, ++++ 80–100%.
Her2/chromosome 17 FISH
FISH assay was carried out with two direct fluorescent-labeled
DNA probes obtained from Pathvysion (Vysis, Abbot AG Diag-
nostic Division, Baar, Switzerland) according to the manufacturer’s
recommended protocol. The centromere region of chromosome 17
was visualized using a spectrum green-labeled probe, the Her2 gene
with a spectrum orange-labeled probe. The probe mixture was
hybridized on paraffin slides containing invasive tumor areas as
controlled on an adjacent H&E-stained section. FISH was per-
formed on all tumors irrespective of the result obtained using IHC.
With regard to scoring, a minimum of 60 non-overlapping nu-
clei were evaluated, and the ratio between Her2 gene and chro-
mosome 17 was assessed. A tumor was considered amplified when
the ratio (Her2/Chrom17) exceeded 2.0 (Fig. 1H). Among diploid
tumor cells, a minimum of five Her2 copies was required for an
amplified status; normal mean Her2 copy number was taken four
signals or less (Fig. 1G).
Statistical analysis
Modifications after chemotherapy compared with results before
treatment were analyzed using McNemar’s test.
Results
Results are summarized in Table 1. Her2 status on IHC
remained unchanged in 15 of 23 patients after chemo-
therapy (65%). Of the patients, 8 exhibited a different
protein expression on mastectomy specimens (35%). The
initial negative (+) IHC was found as positive (++ and
+++, respectively) in 2 patients. Of the cases, 6 positive
cases (++ and +++) on core biopsies were negative on the
mastectomy specimens. Interestingly, 5 of 6 ++ positive
cases on IHC were negative after chemotherapy. Among
+++ positive tumors, there was one case with loss of
protein expression after chemotherapy (case 8); however,
this case showed gene amplification by FISH.
FISH stayed concordant in 20 of 23 patients (87%) on
samples before and after chemotherapy. The initial neg-
ative FISH test in 2 patients showed clear gene amplifi-
cation in both patients after therapy (same patients as on
IHC). Another tumor with gene amplification on core
biopsy was diagnosed as negative using FISH postoper-
Table 1 Summary of results. P values were analyzed using McNemar’s test. n.s. not significant, ER estrogen receptors, PR progesterone
receptors, IHC immunohistochemistry, FISH fluorescence in situ hybridization
n Pos!pos Neg!neg Neg!pos Pos!neg % Changed P values
ER (absent versus + to ++++) 23 18 3 0 2 9 n.s.
PR (absent versus + to ++++) 23 9 9 2 3 22 n.s.
Her2 IHC (-/+ versus ++/+++) 23 5 10 2 6 35 n.s.
Her2 FISH  5 versus 5 copies 23 5 15 2 1 13 n.s.
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atively. All three cases with different Her2 gene status
before and after chemotherapy corresponded to moder-
ately differentiated invasive ductal carcinomas histologi-
cally. The chemotherapy protocol of these three patients
included two to six cycles of fluorouracil–epirubicin. The
six cases with loss of protein expression after chemo-
therapy kept a constant gene profile on the mastectomy
specimens.
Difference in hormone receptor status was observed in
7 of 23 patients (30%). In 2 patients, the originally neg-
ative or weak positive tumor cells were found to express
ER and/or PR strongly; in 5 other patients, the opposite
constellation was seen. No statistically significant
changes were found [P(ER)=0.5; P(PR)=1.0; P(Her2-
IHC)=0.289; P(Her2-FISH)=1.0]. Results of the individ-
ual patients are presented in Table 2.
Discussion
Assessment of Her2 expression and correlation to re-
sponse to primary or neoadjuvant chemotherapy or to
prognosis at advanced breast cancer have been the sub-
jects of several previous studies [5, 6, 14, 19, 23, 25, 27].
A few additional papers addressed the question recently
whether the Her2 protein remains stable during induction
chemotherapy using semi-quantitative and/or immuno-
histochemical methods [3, 4, 9, 16, 18, 21, 24].
Comparison of expression profile on both DNA and
protein level before and after chemotherapy for breast
cancer has not been investigated extensively [7, 11, 22].
We are aware of two previous papers determining Her2
gene characteristics on pre-treatment smears or cores and
post-treatment sections by neoadjuvant treatment modal-
ity using a quantitative and an in situ hybridization
(FISH) methodology, respectively [7, 22].
In our prospective cohort of 22 patients, we analyzed
the Her2 gene and its protein product on core biopsies
prior to induction chemotherapy and on the final mas-
tectomy specimens on each patient using IHC and FISH
methods. We were able to demonstrate in our series that
modification of the Her2 gene after primary chemother-
apy is a rare event, which occurs in a small percentage of
the patients. Her2 gene status was modified in 3 of 23
patients, although this difference was not statistically
significant (13%).
Our results are slightly higher than the observations of
Dagrada et al.: in his series, gene alteration on previously
negative Her2 status occurred only in 4% of the cases.
However, in that study, pre-treatment smears and not core
biopsies were used prior to induction therapy [7]. In a
recent study of Taucher et al., a concordance of 100% was
reached on core biopsies versus post-treatment specimens
when results of IHC and FISH were analyzed combined
[22].
In a similar study of Burstein et al., the preoperative
Her2 status determined using IHC was reconfirmed using
enzyme-linked immunosorbent assay postoperatively. In
this patient selection, all initially negative cases remained
negative; however, 17% of the originally strong positive
cases were found to be negative [4].
Several previous studies addressed gene profile
changing in Her2 status after neoadjuvant chemotherapy
using IHC only; the results, however, represent a wide
range from non-significant to relevant differences [3, 9,
16, 18, 21, 24].
Interestingly, discordance in Her2 status between pri-
mary versus metastatic, respectively, recurrent breast
cancer disease seems to depend on chemotherapy per-
formed in between, when using FISH methodology.
Edgerton et al. found up to 25% discordant Her2 status in
patients treated with chemotherapy; while in a study of
Gansberg, where no chemotherapy was performed, the
difference in Her2 status in primary and metastatic breast
cancer was not significant [8, 11].
The mechanism and exact frequency in Her2 gene
profile changing, loss or acquisition, after neoadjuvant
chemotherapy is not fully understood. It has been sug-
gested in several previous studies that both Her2 over-
expression and gene amplification are early events in the
tumor genesis, and both alterations remain stable during
metastatic process and also for the duration of chemo-
therapy [7, 24].
As indicated by our results as well as in the papers of
Dagrada et al. and Taucher et al., modification of the
Her2 gene does not occur frequently, particularly when
determining Her2 status on the genomic DNA level by
means of FISH methodology [7, 22]. The same seems to
be true for the hormone receptor stability after primary
chemotherapy. The modification of estrogen and proges-
terone receptors could be observed in a small percentage
of our patients after chemotherapy; however, these dif-
ferences were not statistically significant. Our results
appear to confirm similar previous observations in the
literature. In the series of Faneyte et al., Bottini et al. and
Penault-Llorca et al., slight changes in hormone receptor
status could be detected, though none of the differences
was statistically significant either [3, 9, 16].
In a subset of patients, however, the initial Her2 pos-
itive tumors, which are tested negative after induction
therapy, may represent a downregulation of Her2 protein
following antibody therapy; nevertheless, the clinical
Fig. 1 A Low-power view of core biopsies prior to chemotherapy,
revealing large areas of invasive ductal carcinoma [hematoxylin
and eosin (H&E stain)]. B Low-power view of a mastectomy
specimen after chemotherapy, exhibiting abundant fibrosis con-
taining scattered residual tumor cells (H&E stain). C High-power
view of invasive tumor cells, showing uniform nuclei, finely dis-
persed chromatin and isolated mitoses (H&E stain). D High-power
view of tumor cells, exhibiting large hyperchromatic nuclei, coarse
chromatin and numerous nuclear inclusions (H&E stain). E Im-
munohistochemistry (2+) of Her2 protein, evidenced by moderate
circumferential membranous reaction. F Immunohistochemistry
(3+) of Her2 protein by strongly positive membranous staining. G
Non-amplified Her2 gene. Fluorescence in situ hybridization
(FISH) reaction reveals diploid tumor cells (green signal) with
maximum two copies of the Her2 gene (red signal). H Amplified
Her2 gene, FISH reaction demonstrates diploid cells (green signal)
with large clusters and/or 10–12 copies of Her2 genes (red signal)
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significance of this phenomenon is not known at the
moment [4]. Another possibility for discrepant findings
after induction therapy is an intratumoral heterogeneity of
Her2-expressing tumor cells along with tissue sampling
error, both of which could eventually to some extent
contribute to resistance or sensitivity to Herceptin or other
chemotherapeutic agents [4].
In our series, modification of Her2 protein expression
occurred more frequently among ++ positive cases, sug-
gesting that +++ positive tumors using IHC are more
stable during chemotherapeutic processes than ++ cases.
Interestingly, Her2 ++ tumors using IHC in the absence of
gene amplification were more common prior to than after
chemotherapy in our study. Less favorable fixation of
mastectomy specimens after chemotherapy with consec-
utive loss of epitopes and decreased sensitivity for IHC
could be a possible explanation for this phenomenon.
Table 2 Detailed results of individual patients. ER estrogen receptors, PR progesterone receptors, IHC immunohistochemistry, FISH
fluorescence in situ hybridization
Patient no. Before chemotherapy After chemotherapy
ER/PR Her2/IHC Her2/FISH ER/PR Her2/IHC Her2/FISH
1 ++++ ++ Diploid ++++ + Diploid
++++ 2 copies + 2 copies
2 +++ - Diploid +++ - Diploid
- 2 copies - 2 copies
3 + ++ Diploid - - Diploid
- 2 copies - 2 copies
4 +++ - Diploid ++++ + Diploid
+ 2 copies ++ 2 copies
5 + ++ Diploid ++++ - Diploid
- 2 copies - 2 copies
6 - +++ Not done ++++ - Diploid
- Only cytology +++ 2 copies
7 +++ + Diploid +++ + Diploid
- 2 copies - 2 copies
8 - +++ Diploid - - Diploid
- 20 copies ++++ 20 copies
9 ++++ +++ Diploid ++++ +++ Diploid
+ 12–15 copies - 12 copies
10 + - Diploid - - Diploid
- 2 copies - 2 copies
11 ++++ + Di/tetraploid ++++ + Di/tetraploid
++ 2–4 copies ++ 2–4 copies
12 Only cytology Not done ++++ +++ Diploid
- 2 copies
13 +++ + Diploid +++ + Diploid
++++ 2 copies +++ 2 copies
14 ++++ + Di/triploid ++++ +++ Diploid
- 2–3 copies - 12 copies
15 ++++ + Diploid ++++ ++ Diploid
+++ 2 copies +++ 10 copies
16 +++ - Diploid ++ - Diploid
++ 2 copies + 2 copies
17 - - Diploid - - Diploid
- 2 copies + 2 copies
18 +++ +++ Diploid ++++ +++ Diploid
- 8 copies - 10–15 copies
19 - - Diploid No residual tumor
- 2 copies
20 - +++ Diploid - +++ Diploid
- clusters - clusters
21 ++++ ++ Diploid ++++ ++ Diploid
++ 2 copies ++ 2 copies
22 +++ + Diploid ++++ + Diploid
+ 2 copies +++ 2 copies
23 ++++ ++ Diploid ++++ + Diploid
++++ 2 copies - 2 copies
24 + +++ Diploid +++ +++ Diploid
- 6–8 copies - 10–12 copies
25 ++++ + Diploid ++++ + Diploid
++ 8 copies + 2 copies
26 ++++ ++ Diploid ++++ + Diploid
+ 2 copies - 2 copies
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Although predictive factors in a small percentage of
cases can change after neoadjuvant or primary chemo-
therapy, it is advisable to measure these factors more than
once during the disease course.
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